Research Progress of Cancer-associated Fibroblasts in Hematolo- gic Malignancies --Review.
10.19746/j.cnki.issn.1009-2137.2023.06.044
- Author:
Yi-Fan LIU
1
;
Ya-Ming XI
2
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
2. Department of Hematology, The First Hospital of Lanzhou University,Lanzhou 730000, Gansu Province, China.E-mail：xiyaming02@163.com.
- Publication Type:Journal Article
- Keywords:
leukemia;
lymphoma;
multiple myeloma;
cancer-associated fibroblast
- MeSH:
Humans;
Cancer-Associated Fibroblasts/pathology*;
Neoplasms/metabolism*;
Hematologic Neoplasms/metabolism*;
Tumor Microenvironment;
Fibroblasts/pathology*
- From:
Journal of Experimental Hematology
2023;31(6):1885-1889
- CountryChina
- Language:Chinese
-
Abstract:
Cancer-associated fibroblasts （CAF） are a key component of the tumor microenvironment, which can secrete a variety of cytokines, chemokines and growth factors, directly and indirectly support cancer cells, also alter the immune cellular environment by inhibiting the activity of immune effector cells and recruiting immunosuppressive cells, thereby allowing cancer cells to evade immune surveillance. CAF has been proven to be associated with the development, progression, and poor prognosis of solid tumors. However, the role of CAF in hematological malignancies is still unclear. This article reviews the research progress of CAF in hematological malignancies.
